Recombinant Human Complement Component C1s Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00629P-100UG
Human Complement Component C1s on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human Complement Component C1s Protein, Active
Beta LifeScience
SKU/CAT #: BLK-00629P-100UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
| Description | Recombinant Human Complement Component C1s Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Glu16-Asp688. |
| Purity | > 95% as determined by Tris-Bis PAGE |
| Accession | P09871 |
| Target Symbol | Complement Component C1s |
| Species | Human |
| Expression System | HEK293 |
| Tag | C-His |
| Expression Range | Glu16-Asp688 |
| Mol. Weight | The protein has a predicted MW of 75.98 kDa. Due to enzyme lysis glycosylation, the protein migrates to 55-60 kDa (light chain), 32-35 kDa (heavy chain) and 76-96 kDa based on Tris-Bis PAGE result. |
| Form | Lyophilized |
| Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin | Less than 1EU per ug by the LAL method. |
| Activity | Immobilized Human Complement Component C1S, His Tag at 0.5ug/ml (100ul/well) on the plate. Dose response curve for Anti-C1S Antibody, hFc Tag with the EC50 of 9.6ng/ml determined by ELISA. Contact us for detailed testing images. |
| Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping | Shipped at ambient temperature. |
| Gene Background | Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS). |
